Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
| Status: | Archived |
|---|---|
| Conditions: | Neurology, Psychiatric |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
The purpose of this study is to determine if Abilify will reduce tics (repetitive,
uncontrollable movements or vocalizations) in children and adolescents ages 7-18 with
Tourette’s Disorder (TD) or a chronic motor tic disorder (either repetitive, uncontrollable
movements or vocalizations).
The aims of this study are to obtain systematic data regarding dosing and safety of
aripiprazole (Abilify) in the treatment of youth with Tourette’s Disorder (TD). Tourette’s
Disorder is characterized by multiple motor (more than one uncontrollable movement) and
vocal tics (vocal outbursts) which have been present for more than 1 year, with onset before
the age of 18. The disorder causes marked distress in social, occupational or other
important areas of functioning. Abilify has been approved by the United States Food and
Drug Administration (FDA) to treat adults with schizophrenia but has not been approved to
treat Tourette’s Disorder (TD) so it is considered experimental or investigational in this
study.
We found this trial at
1
site
New York University Langone Medical Center NYU NYU Langone Medical Center, a world-class, patient-centered, integrated,...
Click here to add this to my saved trials
